In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Savara Inc.

Italfarmaco Options Inhaled Teicoplanin For MRSA Lung Infections

Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.

 

Deals Infectious Diseases

In Hindsight, Savara Wishes It Led With Patient-Reported Secondary Endpoint For Molgradex

Orphan lung disease firm tries to sell Phase III setback in aPAP as a “successful failed study” but investors disagree, cutting Savara’s share price by three-quarters. Biotech hopes to talk with regulators after deeper dive into dataset.

Clinical Trials Drug Approval Standards

Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear

Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.

Clinical Trials Research & Development

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Aravas Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Savara Inc.
  • Senior Management
  • Rob Neville, Chmn. & CEO
    Dave Lowrance, CFO
    Taneli Jouhikainen, MD, PhD, COO
    Peter Ginsberg, VP, Bus. Dev.
    Cecilia Ganslandt, MD, Head, Medical Affairs
  • Contact Info
  • Savara Inc.
    Phone: (512) 961-1891
    6836 Bee Cave Rd., Bldg. 3, Ste. 200
    Austin, TX 78746
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register